A 2022 study published in the Journal of Family Medicine and Primary Care, highlights the occurrence of VITT. “Vaccination is supposed to be the most reliable means to end the COVID 19 pandemic, but recently there have been reports of thrombosis and thrombocytopenia in patients receiving the vaccine especially ChAdOx1 nCoV-19 (AstraZeneca University of Oxford and Serum Institute of India). This has been termed as vaccine-induced immune thrombotic thrombocytopenia (VITT), thrombosis with thrombocytopenia syndrome (TTS) and vaccine-induced prothrombotic immune thrombocytopenia (VIPIT),” it says. “The incidence of VITT ranges widely from one case per 26,000 to one case per 127,000 doses of AstraZeneca/COVISHIELD administered in countries like Norway and Denmark reporting the highest rates,” the report by researchers from the Department of Medicine, Tata Main Hospital, Bistupur, Jamshedpur, Jharkhand, India adds.